Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much [Seeking Alpha]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Seeking Alpha
The approval of Fanapt for bipolar disorder may not significantly contribute to Vanda's bottom line as there are already several drugs approved for this indication. Despite a strong balance sheet, Vanda's future is heavily reliant on expanding existing drugs indications and new drug successes. Maintain "Hold" recommendation: Fanapt's bipolar indication is unlikely to significantly impact revenue; the company faces moderate-to-high risk. Vanda: Assessing Fanapt's Impact on Bipolar Treatment Market As of my July "hold" recommendation Vanda Pharmaceuticals Inc. NASDAQ: VNDA ) stock now is down 17%. During the same period, the S&P 500 Index ( SP500 ) has returned 12%. Back then, I shed some light on the company's declining sales of their lead drug, Hetlioz, due to generic competition. I also expressed uncertainty regarding their pipeline. On Wednesday, the company announced the FDA had approved Fanapt for the "acute treatment of manic or mixed episodes associated with bipolar I
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024PR Newswire
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsGlobeNewswire
- Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know [Yahoo! Finance]Yahoo! Finance
VNDA
Earnings
- 2/7/24 - Beat
VNDA
Analyst Actions
- 2/9/24 - TheStreet
VNDA
Sec Filings
- 5/3/24 - Form 8-A12B/A
- 5/3/24 - Form 8-K
- 4/29/24 - Form ARS/A
- VNDA's page on the SEC website